Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in RBC Membranopathies and CDAII
NCT05935202Phase 2Not yet recruiting
- Sponsor
- EuroBloodNet Association
- Start
- Dec 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of mitapivat in erythrocyte membrane disorder, Congenital Dyserythropoietic Anemia Type 2, sponsored by EuroBloodNet Association. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
mitapivat
03
Conditions
erythrocyte membrane disorderCongenital Dyserythropoietic Anemia Type 2
Beyond the preview
Go deeper on NCT05935202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05935202.